Heron Therapeutics, a biotechnology company, operates in the health care sector, leveraging its proprietary drug delivery technology to enhance therapeutic profiles and reformulate existing therapies.

Heron Therapeutics Inc, a biotech company with innovative biochronomer technology, has experienced significant stock price volatility, but recent trading activity suggests a bullish sentiment among investors.

Heron Therapeutics has announced the appointment of Mark Hensley as its new Chief Operating Officer, as part of the company’s efforts to strengthen its leadership team and drive forward its mission in the biotechnology industry.